Reta Passes Another Trial

[ftv10hb]

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

www.cnbc.com

Curious if anyone knows the name of the similar drug mentioned at the end that Novo acquired? Clicked on the link to the press release from last year and it was just referred to as UBT251, wondering if there’s a common name it’s known by since then or still TBD

 

[Estarossa19]

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

www.cnbc.com

Curious if anyone knows the name of the similar drug mentioned at the end that Novo acquired? Clicked on the link to the press release from last year and it was just referred to as UBT251, wondering if there’s a common name it’s known by since then or still TBD

Thanks for the article! From my knowledge that drug from novo still has one of those numbered names for now.

 

[WeezinDaJuice]

UBT251

https://www.fiercebiotech.com/biotech/novo-nordisk-pens-2b-deal-triple-g-agonist-tied-15-weight-loss-12-weeks

 

[MFGamesta]

So Novo is now using Chinese peptides. LoL

 

[OregonSunshine]

Does anyone know if any of our friends in China are making UBT251 yet? I think I read somewhere that it's trickier to synthesize than tirz and reta so it might be awhile before we see it widely available.

 

[JustMakeItHappen]

This shit is so interesting! what a time to be alive lol

 

[AcadiaPeptides]

Interesting data, but I think people are getting ahead of themselves. Retatrutide looks powerful, but we’re still comparing across different trials, populations, and dosing schedules. That makes the “17% weight loss” headline a lot less clean than it sounds.
The dropout rate may be low, but we don’t know how tolerability will look once this moves into real‑world use, especially with a drug that hits three pathways at once. And Lilly hasn’t filed for approval yet, which tells me the full picture isn’t as straightforward as the press release tone suggests.
Until we see head‑to‑head studies—or at least more transparent safety data—I’m not convinced this is the game‑changer people are hyping. The triple‑agonist space has promise, but it also has a lot of unanswered questions.

 

[CornPop]

Interesting data, but I think people are getting ahead of themselves. Retatrutide looks powerful, but we’re still comparing across different trials, populations, and dosing schedules. That makes the “17% weight loss” headline a lot less clean than it sounds.
The dropout rate may be low, but we don’t know how tolerability will look once this moves into real‑world use, especially with a drug that hits three pathways at once. And Lilly hasn’t filed for approval yet, which tells me the full picture isn’t as straightforward as the press release tone suggests.
Until we see head‑to‑head studies—or at least more transparent safety data—I’m not convinced this is the game‑changer people are hyping. The triple‑agonist space has promise, but it also has a lot of unanswered questions.

Yeah I’m taking tirz too